Pyridines

• 

  Subject Areas on Research

  • 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. 
  • 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. 
  • 2-[18F]F-A-85380: a PET radioligand for alpha4beta2 nicotinic acetylcholine receptors. 
  • 28-day toxicology test: indenopyridine RTI 4587-056 in male Sprague-Dawley rats. 
  • 5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with low picomolar affinity for alpha4beta2 nicotinic acetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomography. 
  • A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease. 
  • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. 
  • A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). 
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. 
  • A cost analysis of the impact of a new intravenous antihypertensive in managing perioperative blood pressure during cardiac surgery. 
  • A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. 
  • A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. 
  • A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. 
  • A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). 
  • A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 
  • A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. 
  • A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). 
  • A photolabile ligand for light-activated release of caged copper. 
  • A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. 
  • A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome. 
  • A simplified method for the measurement of nonmetabolized 2-[18F]F-A-85380 in blood plasma using solid-phase extraction. 
  • A system to monitor statin-induced myopathy in individual engineered skeletal muscle myobundles. 
  • A tissue-engineered human trabecular meshwork hydrogel for advanced glaucoma disease modeling. 
  • AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. 
  • Activation of p38 mitogen-activated protein kinase in spinal microglia contributes to incision-induced mechanical allodynia. 
  • Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 
  • Acute renal failure and pigmentation due to phenazopyridine (Pyridium). 
  • Adolescent morphine exposure affects long-term microglial function and later-life relapse liability in a model of addiction. 
  • Adverse effects of nifedipine therapy on hypertrophic obstructive cardiomyopathy. 
  • Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation. 
  • Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. 
  • Aminopyridines and sparteine as inhibitors of membrane potassium conductance: effects on Myxicola giant axons and the lobster neuromuscular junction. 
  • An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). 
  • Angiotensin protects cortical neurons from hypoxic-induced apoptosis via the angiotensin type 2 receptor. 
  • Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. 
  • Antidepressant actions of histone deacetylase inhibitors. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. 
  • Antithrombotic treatment strategies after PCI. 
  • Antiulcer Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidzao[1,2-α]pyridines 
  • Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective and Metabolic Properties of Substituted Imidazo-[1,2,-α]-pyridines 
  • Antiulcer Agents. 4. Conformational Considerations and the Antiulcer Activity of Substituted Imidazol[1,2-α]pyridines and Related Analogs 
  • Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells. 
  • Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. 
  • Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). 
  • Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. 
  • Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). 
  • Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. 
  • Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. 
  • Atom transfer radical polymerization preparation and photophysical properties of polypyridylruthenium derivatized polystyrenes. 
  • Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. 
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Basic matrices for the matrix-assisted laser desorption/ionization mass spectrometry of proteins and oligonucleotides. 
  • Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Blockade of angiotensin II type 2 receptor by PD123319 inhibits osteogenic differentiation of human mesenchymal stem cells via inhibition of extracellular signal-regulated kinase signaling. 
  • Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice. 
  • Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. 
  • CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. 
  • Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. 
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. 
  • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. 
  • Cabozantinib in genitourinary malignancies. 
  • Cabozantinib in ovarian clear cell cancers: UnMET expectations. 
  • Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. 
  • Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives. 
  • Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. 
  • Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction. 
  • Cellular requirements for the small molecule forchlorfenuron to stabilize the septin cytoskeleton. 
  • Cellular senescence: from anti-cancer weapon to anti-aging target. 
  • Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine. 
  • Cerivastatin Nanoliposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension. 
  • Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? 
  • Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series. 
  • Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. 
  • Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. 
  • Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 
  • Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. 
  • Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. 
  • Clevidipine in adult cardiac surgical patients: a dose-finding study. 
  • Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials. 
  • Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial. 
  • Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. 
  • Clinical applications of antiplatelet therapy. 
  • Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. 
  • Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 
  • Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission. 
  • Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. 
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. 
  • Combination antithrombotic therapies. 
  • Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. 
  • Comparison of myocardial protection with nifedipine and potassium. 
  • Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. 
  • Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. 
  • Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. 
  • Continuous anticoagulation with catheter ablation: answers and questions. 
  • Control of basement membrane remodeling and epithelial branching morphogenesis in embryonic lung by Rho and cytoskeletal tension. 
  • Controlled release of etoricoxib from poly(ester urea) films for post-operative pain management. 
  • Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 
  • Coronary constriction to angiotensin II is enhanced by endothelial superoxide production in sheep programmed by dexamethasone. 
  • Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. 
  • Cyclic mechanical stress and trabecular meshwork cell contractility. 
  • Cytosolic phospholipase A(2) activity associated with nuclei is not inhibited by arachidonyl trifluoromethyl ketone in macrophages stimulated with receptor-recognized forms of alpha(2)-macroglobulin. 
  • DVT: a new era in anticoagulant therapy. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. 
  • Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands. 
  • Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Development of next-generation photolabile copper cages with improved copper binding properties. 
  • Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei. 
  • Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. 
  • Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. 
  • Differential efficacies of the nicotinic α4β2 desensitizing agents in reducing nicotine self-administration in female rats. 
  • Differentiation of erythroleukemia cells in vitro: properties of chemical inducers. 
  • Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). 
  • Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. 
  • Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. 
  • Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control. 
  • Dual hepatic metabolism of cerivastatin--clarifications. 
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. 
  • Edoxaban and the need for outcomes-based NOAC dosing. 
  • Edoxaban in the secondary prevention of VTE. 
  • Edoxaban versus warfarin in patients with atrial fibrillation. 
  • Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. 
  • Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. 
  • Effect of metabotropic glutamate 5 receptor antagonists on morphine efficacy and tolerance in rats with neuropathic pain. 
  • Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. 
  • Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. 
  • Effects of Selonsertib in Patients with Diabetic Kidney Disease. 
  • Effects of Y27632 on keratinocyte procurement and wound healing. 
  • Effects of atypical anxiolytic N-phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats. 
  • Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. 
  • Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats. 
  • Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. 
  • Effects of pharmacologic inhibition of protein geranylgeranyltransferase type I on aqueous humor outflow through the trabecular meshwork. 
  • Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. 
  • Effects of sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats. 
  • Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 
  • Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor β2-/- and α7-/- mice. 
  • Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. 
  • Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. 
  • Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. 
  • Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. 
  • Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. 
  • Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. 
  • Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). 
  • Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). 
  • Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. 
  • Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction. 
  • Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. 
  • Enantioselective diene Cyclization/Hydrosilylation catalyzed by optically active palladium bisoxazoline and pyridine-oxazoline complexes. 
  • Endothelin-1 blockade corrects mesenteric hypoperfusion in a porcine low cardiac output model. 
  • Engineered site-directed labeling of nicotinic acetylcholine receptors using reactive epibatidine derivatives: appraisal of epibatidine-docking models in neuronal and muscular receptors. 
  • Essential role of AT1A receptor in the development of 2K1C hypertension. 
  • Evaluating lemborexant for the treatment of insomnia. 
  • Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Exceptionally potent antispermatogenic compounds from 8-halogenation of (4aRS,5SR,9bRS)-hexahydroindeno-[1,2-c]pyridines. 
  • Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis. 
  • Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. 
  • Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. 
  • Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. 
  • Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. 
  • Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). 
  • Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). 
  • Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. 
  • Fast endocytosis is inhibited by GABA-mediated chloride influx at a presynaptic terminal. 
  • First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. 
  • Fluorescent epibatidine agonists for neuronal and muscle-type nicotinic acetylcholine receptors. 
  • Frequency of atazanavir-associated leukocyturia development and renal function decline. 
  • Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. 
  • Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma. 
  • Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. 
  • Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). 
  • Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. 
  • HEPATIC ALDEHYDE OXIDASE. 3. THE SUBSTRATE-BINDING SITE. 
  • HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. 
  • Heart rate decrease during crizotinib treatment and potential correlation to clinical response. 
  • Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease. 
  • Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. 
  • Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. 
  • Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. 
  • High affinity binding of [3H]epibatidine to rat brain membranes. 
  • High levels of glucose stimulate angiotensinogen gene expression via the P38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. 
  • Histamine stimulates brain phospholipid turnover through a direct, H-1 receptor-mediated mechanism. 
  • Hyperpolarization of "Neat" Liquids by NMR Signal Amplification by Reversible Exchange. 
  • Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). 
  • Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. 
  • Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. 
  • Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. 
  • Immediate and long-term consequences of vascular toxicity during zebrafish development. 
  • Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. 
  • Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. 
  • In vivo evidence of the specificity of effects of GABA(A) receptor modulating medications. 
  • In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. 
  • Increased Metabotropic Glutamate Receptor 5 Signaling Underlies Obsessive-Compulsive Disorder-like Behavioral and Striatal Circuit Abnormalities in Mice. 
  • Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. 
  • Inflammation influences vascular remodeling through AT2 receptor expression and signaling. 
  • Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. 
  • Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells. 
  • Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice. 
  • Inhibition of Rho-kinase induces alphaB-crystallin expression in lens epithelial cells. 
  • Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. 
  • Inhibition of barnacle larval settlement and crustacean toxicity of some hoplonemertine pyridyl alkaloids. 
  • Inhibition of bladder activity by 5-hydroxytryptamine1 serotonin receptor agonists in cats with chronic spinal cord injury. 
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. 
  • Inhibition of spinal p38 MAPK prevents articular neutrophil infiltration in experimental arthritis via sympathetic activation. 
  • Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. 
  • Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. 
  • Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. 
  • Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. 
  • Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. 
  • Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. 
  • Isavuconazole for treatment of rare invasive fungal diseases. 
  • Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. 
  • Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Isolation and structure of antagonists of chemokine receptor (CCR5). 
  • Isomeric N-alkylpyridylporphyrins and their Zn(II) complexes: inactive as SOD mimics but powerful photosensitizers. 
  • Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. 
  • JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. 
  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. 
  • LIGHT-SABRE enables efficient in-magnet catalytic hyperpolarization. 
  • Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. 
  • Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. 
  • Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. 
  • Lonafarnib for cancer and progeria. 
  • Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. 
  • Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. 
  • Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. 
  • MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. 
  • Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. 
  • Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. 
  • Measurement of the alpha4beta2* nicotinic acetylcholine receptor ligand 2-[(18)F]Fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study. 
  • Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). 
  • Mechanisms of activation of the RAW264.7 macrophage cell line by transfected mammalian DNA. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Membrane Transporters Involved in the Antimicrobial Activities of Pyrithione in Escherichia coli . 
  • Merkel cell polyomavirus small tumour antigen activates the p38 MAPK pathway to enhance cellular motility. 
  • Microtesla SABRE enables 10% nitrogen-15 nuclear spin polarization. 
  • Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. 
  • Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. 
  • Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling. 
  • Moving upstream in the war on WNTs. 
  • Mutually augmenting interactions of dextromethorphan and sazetidine-A for reducing nicotine self-administration in rats. 
  • N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. 
  • N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. 
  • NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. 
  • Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. 
  • Nicotinic attention-deficit/hyperactivity disorder treatment. 
  • Nociceptors are interleukin-1beta sensors. 
  • Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. 
  • Novel medication targets for the treatment of alcoholism: preclinical studies. 
  • Novel oral anticoagulants in gastroenterology practice. 
  • Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. 
  • Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. 
  • Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 
  • Oral sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, reduces nicotine self-administration in rats. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. 
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 
  • Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis. 
  • Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. 
  • P38MAP kinase, but not phosphoinositol-3 kinase, signal downstream of glutamine-mediated fibronectin-integrin signaling after intestinal injury. 
  • PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. 
  • PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. 
  • PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. 
  • PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. 
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. 
  • Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. 
  • Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects. 
  • Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. 
  • Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. 
  • Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. 
  • Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. 
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 
  • Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. 
  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. 
  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. 
  • Phenotypes of trypsin- and collagenase-prepared bovine corneal endothelial cells in the presence of a selective Rho kinase inhibitor, Y-27632. 
  • Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast. 
  • Prasugrel. 
  • Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. 
  • Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. 
  • Problems with the randomized discontinuation design. 
  • Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. 
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 
  • Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. 
  • Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. 
  • Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). 
  • Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. 
  • Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. 
  • Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. 
  • Radiosynthesis of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-[(11)C]methyl-2-(S)-pyrrolidinylmethoxy)pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. 
  • Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. 
  • Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. 
  • Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. 
  • Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. 
  • Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. 
  • Recombination between homologous chromosomes induced by unrepaired UV-generated DNA damage requires Mus81p and is suppressed by Mms2p. 
  • Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. 
  • Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. 
  • Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. 
  • Regulation of cofilin phosphorylation in glomerular podocytes by testis specific kinase 1 (TESK1). 
  • Renal vascular reactivity in mice: AngII-induced vasoconstriction in AT1A receptor null mice. 
  • Reply to B. Rini et al and S. Buti et al. 
  • Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. 
  • Reserpine-like effects of harmine on isolated adrenal medullary vesicles. 
  • Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. 
  • Rho A/Rho kinase: human umbilical artery mRNA expression in normal and pre eclamptic pregnancies and functional role in isoprostane-induced vasoconstriction. 
  • Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells. 
  • Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. 
  • Role of 14-3-3-mediated p38 mitogen-activated protein kinase inhibition in cardiac myocyte survival. 
  • Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation. 
  • S1P₂ receptor regulation of sphingosine-1-phosphate effects on conventional outflow physiology. 
  • SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials. 
  • Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. 
  • Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. 
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 
  • Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. 
  • Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. 
  • Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies. 
  • Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Should patients on vitamin K antagonists be treated differently? 
  • Siroheme and sirohydrochlorin. The basis for a new type of porphyrin-related prosthetic group common to both assimilatory and dissimilatory sulfite reductases. 
  • Site-Selective Copper-Catalyzed Amination and Azidation of Arenes and Heteroarenes via Deprotonative Zincation. 
  • Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. 
  • Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. 
  • Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. 
  • Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Sotorasib for previously treated colorectal cancers with KRAS^G12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. 
  • Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. 
  • Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. 
  • Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost. 
  • Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. 
  • Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • Strong means slow: dynamic contributions to the bulk mechanical properties of supramolecular networks. 
  • Structural basis of small molecule ATPase inhibition of a human mitotic kinesin motor protein. 
  • Structure and dynamics of an extended conjugated NLO chromophore within an amphiphilic 4-helix bundle peptide by molecular dynamics simulation. 
  • Structure-activity studies of 2,3,4,4a,5,9b-hexahydroindeno[1,2-c]pyridines as antispermatogenic agents for male contraception. 
  • Subchronic effects of plant alkaloids on anxiety-like behavior in zebrafish. 
  • Sublethal exposure to pyriproxyfen does not impair the abilities of the backswimmer Buenoa amnigenus to prey upon Aedes aegypti larvae. 
  • Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816. 
  • Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. 
  • Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation. 
  • Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma. 
  • Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. 
  • Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors. 
  • Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. 
  • Synthesis and iron sequestration equilibria of novel exocyclic 3-hydroxy-2-pyridinone donor group siderophore mimics. 
  • Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation. 
  • Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? 
  • TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. 
  • TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation. 
  • TT-301 inhibits microglial activation and improves outcome after central nervous system injury in adult mice. 
  • Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). 
  • Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). 
  • Tezosentan normalizes hepatomesenteric perfusion in a porcine model of cardiac tamponade. 
  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. 
  • The Absence of Quadrupolar Nuclei Facilitates Efficient 13 C Hyperpolarization via Reversible Exchange with Parahydrogen. 
  • The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. 
  • The anti-inflammatory potential of selective cholinergic agonists. 
  • The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders. 
  • The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. 
  • The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. 
  • The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. 
  • The possibility of preventing functional impairment due to sleep loss by pharmacologically enhancing sleep. 
  • The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The role of angiotensin II in stress urinary incontinence: A rat model. 
  • The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. 
  • The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. 
  • The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. 
  • The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. 
  • The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. 
  • Thermodynamics of pyridine coordination in 1,4-phenylene bridged bimetallic (Pd, Pt) complexes containing two N,C,N' motifs, 1,4-M2-[C6(CH2NR2)4-2,3,5,6]. 
  • Thienopyridine efficacy and cigarette smoking status. 
  • Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid. 
  • Three ring posttranslational circuses: insertion of oxazoles, thiazoles, and pyridines into protein-derived frameworks. 
  • Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. 
  • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. 
  • Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. 
  • Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. 
  • Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. 
  • Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. 
  • Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). 
  • Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Tunable molecular tension sensors reveal extension-based control of vinculin loading. 
  • Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. 
  • URMC-099 prophylaxis prevents hippocampal vascular vulnerability and synaptic damage in an orthopedic model of delirium superimposed on dementia. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Unveiling coherently driven hyperpolarization dynamics in signal amplification by reversible exchange. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • Urolithiasis under atazanavir boosted and tenofovir therapy: a case report. 
  • Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. 
  • Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). 
  • Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). 
  • VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. 
  • Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. 
  • Variation in toxicity of copper pyrithione among populations and families of the barnacle, Balanus amphitrite. 
  • Vascular smooth muscle cell migration induced by domains of thrombospondin-1 is differentially regulated. 
  • Vasodilators in the treatment of acute heart failure: what we know, what we don't. 
  • Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. 
  • Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). 
  • Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). 
  • Vesicular zinc promotes presynaptic and inhibits postsynaptic long-term potentiation of mossy fiber-CA3 synapse. 
  • Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. 
  • Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. 
  • Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). 
  • Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Vorapaxar in the secondary prevention of atherothrombotic events. 
  • Vorapaxar in the treatment of cardiovascular diseases. 
  • Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. 
  • Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. 
  • Vorapaxar: a novel protease-activated receptor-1 inhibitor. 
  • Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. 
  • Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. 
  • Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. 
  • Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. 
  • Zolpidem for persistent insomnia in SSRI-treated depressed patients. 
  • Zolpidem use and risk of fractures: a systematic review and meta-analysis. 
  • [3H]zolpidem binding in alcohol-preferring and non-preferring rat brain. 
  • beta-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase. 
  • p38 MAPK, microglial signaling, and neuropathic pain. 
  • p38 Mitogen-activated protein kinase plays a stimulatory role in hepatic gluconeogenesis. 
  • p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. 
  • p38 mitogen-activated protein kinase regulates growth factor-induced mitogenesis of rat pulmonary myofibroblasts. 
  • α4β2 Nicotinic receptor desensitizing compounds can decrease self-administration of cocaine and methamphetamine in rats. 
  • β-Arrestin-2-Dependent Signaling Promotes CCR4-mediated Chemotaxis of Murine T-Helper Type 2 Cells. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering